



# Migraine:

## Selected Patient Reported Outcome Measures (PROMs)

PROMs can be used to help improve migraine screening, diagnosis, and management by<sup>1</sup>:

- ✓ Assessing quality of life (QoL), burden of disease, disability, impact of headache on daily life, and work productivity
- ✓ Helping evaluate effectiveness and optimization of interventions

Domain	PROM		Number of Questions	Domains Included	Use in Acute or Preventive
Screening and diagnosis	ID Migraine™ Screener <sup>2</sup>	+	3	<ul style="list-style-type: none"> <li>• Photophobia</li> <li>• Impairment</li> <li>• Nausea</li> </ul>	NA
Treatment assessment	Migraine Disability Assessment (MIDAS) <sup>3,4*</sup>	+	5 scorable questions <sup>a</sup>	<ul style="list-style-type: none"> <li>• School, social, and employment impact</li> <li>• Frequency of headache</li> <li>• Intensity of headache pain</li> </ul>	Preventive
	Migraine Treatment Optimization Questionnaire (MTOQ-5) <sup>5*</sup>	+	5	<ul style="list-style-type: none"> <li>• Functioning</li> <li>• Rapid relief</li> <li>• Consistency of relief</li> <li>• Risk of recurrence</li> <li>• Tolerability</li> </ul>	Acute
	Migraine Assessment of Current Therapy (Migraine-ACT) <sup>6</sup>	+	4	<ul style="list-style-type: none"> <li>• Consistency of response</li> <li>• Global assessment of relief</li> <li>• Headache impact</li> <li>• Emotional response</li> </ul>	Acute
	Migraine-Specific QoL Questionnaire 2.1 (MSQv2.1) <sup>7*</sup>	+	14	<ul style="list-style-type: none"> <li>• Role-function restrictive</li> <li>• Role-function preventive</li> <li>• Emotional functions</li> </ul>	Preventive
	Patient Global Impression of Change (PGIC) <sup>8*</sup> <i>Not migraine-specific</i>	+	1	<ul style="list-style-type: none"> <li>• Single score on continuous scale: Impression of change in overall status after treatment</li> </ul>	Preventive
Functioning and HRQoL	Work Productivity and Activity Impairment Questionnaire: Migraine (WPAI:Migraine) <sup>8,9</sup>	+	6	<ul style="list-style-type: none"> <li>• Work time missed</li> <li>• Work productivity loss</li> <li>• Impairment at work</li> <li>• Activity impairment</li> </ul>	Preventive
	Headache Impact Test-6 (HIT-6) <sup>10*</sup>	+	6	<ul style="list-style-type: none"> <li>• Impact of headache (pain, impairment, emotional distress)</li> </ul>	Preventive
	Functional Impairment Scale (FIS) <sup>11,12</sup> <i>Not migraine-specific</i>	+	4	<ul style="list-style-type: none"> <li>• Functional status</li> </ul>	Acute

\*A potential clinically meaningful difference in score on the questionnaire may be available<sup>1</sup>

<sup>a</sup>7 questions in total

1. Dikmen PY, et al. *Heliyon*. 2023;9(5):e16187; 2. Lipton RB, et al. *Neurology*. 2003;61(3):375-382; 3. Lipton RB, et al. *Headache*. 2001;41(9):854-861; 4. Stewart WF, et al. *Pain*. 2000;88(1):41-52; 5. Lipton RB, et al. *Cephalalgia*. 2009;29(7):751-759; 6. Dowson AJ, et al. *Curr Med Res Opin*. 2004;20(7):1125-1135; 7. Cole JC, et al. *Cephalalgia*. 2009;29(11):1180-1187; 8. Reilly MC, et al. *Pharmacoeconomics*. 1993;4(5):353-365; 9. Ford JH, et al. *J Patient Rep Outcomes*. 2023;7(1):34; 10. Yang M, et al. *Cephalalgia*. 2011;31(3):357-367; 11. Tassorelli C, et al. *Cephalalgia*. 2018;38(5):815-832; 12. NINDS Common Data Elements. [Functional Impairment Scale](#). Accessed April 24, 2025.



# Migraine:

## Selected Patient Reported Outcome Measures (PROMs)

PROMs can be used to help improve migraine management by<sup>1</sup>:

- ✓ Assessing quality of life (QoL), burden of disease, disability, impact of headache on daily life, and work productivity
- ✓ Helping evaluate effectiveness and optimization of interventions

### Screening and Diagnosis



## ID Migraine™ Screener Summary



The 3-item ID Migraine™ Screener is a validated and reliable tool that may help rapidly diagnose migraine in the primary care setting.<sup>1</sup>

If the patient responds affirmatively to 2 or all 3 items, a migraine diagnosis is likely.<sup>1,2a</sup>

### ID Migraine™ screener questions:

1. Has a headache limited your activities for a day or more in the last 3 months?
2. Are you nauseated or sick to your stomach when you have a headache?
3. Does light bother you when you have a headache?



ID Migraine™ available [here](#)

Clicking this link will take you to an external site

<sup>a</sup>Testing positive for 2 of the 3 items yields a sensitivity of 0.81 (95% confidence interval 0.77–0.85).

1. Lipton RB, et al. *Neurology*. 2003;61(3):375–382; 2. de Mattos ACMT, et al. *Arq Neuropsiquiatr* 2017;75(7):446-450.

### Functioning and QoL

Impairment Questionnaire:  
Migraine (WPAI:Migraine)<sup>8,9</sup>

- (impairment at work)
- Work productivity loss
- Activity impairment

Headache Impact  
Test-6 (HIT-6)<sup>10</sup>



6

- Impact of headache (pain, impairment, emotional distress)

Preventive

Functional Impairment  
Scale (FIS)<sup>11,12,b</sup>



4

- Functional status

Both

Clinically meaningful difference available.

<sup>a</sup>7 questions in total; <sup>b</sup>Not migraine-specific.

1. Dikmen PY, et al. *Heliyon*. 2023;9(5):e16187; 2. Lipton RB, et al. *Neurology*. 2003;61(3):375-382; 3. Lipton RB, et al. *Headache*. 2001;41(9):854-861; 4. Stewart WF, et al. *Pain*. 2000;88(1):41-52; 5. Lipton RB, et al. *Cephalalgia*. 2009;29(7):751-759; 6. Dowson AJ, et al. *Curr Med Res Opin*. 2004;20(7):1125-1135; 7. Cole JC, et al. *Cephalalgia*. 2009;29(11):1180-1187; 8. Reilly MC, et al. *Pharmacoeconomics*. 1993;4(5):353-365; 9. Ford JH, et al. *J Patient Rep Outcomes*. 2023;7(1):34; 10. Yang M, et al. *Cephalalgia*. 2011;31(3):357-367; 11. Tassorelli C, et al. *Cephalalgia*. 2018;38(5):815-832; 12. [Functional Impairment Scale](#). Accessed April 24, 2025.



# Migraine:

## Selected Patient Reported Outcome Measures (PROMs)

PROMs can be used to help improve migraine management by<sup>1</sup>:

- ✓ Assessing quality of life (QoL), burden of disease, disability, impact of headache on daily life, and work productivity
- ✓ Helping evaluate effectiveness and optimization of interventions

### Treatment assessments



## Migraine Disability Assessment (MIDAS) Summary



MIDAS is a validated tool that quantifies the number of days an individual missed/had reduced productivity at work/home/social events over the past 3 months.<sup>1-3</sup>

Based on questions 1–5, the number of days are categorized into the following disability grades<sup>1-3</sup>:

I: 0–5 = little/no disability; II: 6–10 = mild; III: 11–20 = moderate; and IV:  $\geq 21$  = severe.

**Q1.** On how many days in the last 3 months did you miss work or school because of your headaches?

**Q2.** How many days in the last 3 months was your productivity at work or school reduced by half or more because of your headaches?

**Q3.** On how many days in the last 3 months did you not do household work because of your headaches?

**Q4.** How many days in the last 3 months was your productivity in household work reduced by half or more because of your headaches?

**Q5.** On how many days in the last 3 months did you miss family, social, or leisure activities because of your headaches?

**What your physician will need to know:**

**A.** On how many days in the last 3 months did you have a headache?

**B.** On a scale of 0–10, on average, how painful were these headaches?



**MIDAS available [here](#)**

Clicking this link will take you to an external site

1. Lipton RB, et al. *Headache*. 2001;41(9):854-861; 2. Stewart WF, et al. *Pain*. 2000;88(1):41-52; 3. Yang M, et al. *Cephalalgia*. 2010;31(3):357-367; 4. Dikmen PY, et al. *Heliyon*. 2023;9(5):e16187; 5. American Headache Society. *Headache*. 2019;59(1):1-18.

1. Dikmen PY, et al. *Heliyon*. 2023;9(5):e16187; 2. Lipton RB, et al. *Neurology*. 2003;61(3):375-382; 3. Lipton RB, et al. *Headache*. 2001;41(9):854-861; 4. Stewart WF, et al. *Pain*. 2000;88(1):41-52; 5. Lipton RB, et al. *Cephalalgia*. 2009;29(7):751-759; 6. Dowson AJ, et al. *Curr Med Res Opin*. 2004;20(7):1125-1135; 7. Cole JC, et al. *Cephalalgia*. 2009;29(11):1180-1187; 8. Reilly MC, et al. *Pharmacoeconomics*. 1993;4(5):353-365; 9. Ford JH, et al. *J Patient Rep Outcomes*. 2023;7(1):34; 10. Yang M, et al. *Cephalalgia*. 2011;31(3):357-367; 11. Tassorelli C, et al. *Cephalalgia*. 2018;38(5):815-832; 12. [Functional Impairment Scale](#). Accessed April 24, 2025.



# Migraine:

## Selected Patient Reported Outcome Measures (PROMs)

PROMs can be used to help improve migraine management by<sup>1</sup>:

- ✓ Assessing quality of life (QoL), burden of disease, disability, impact of headache on daily life, and work productivity
- ✓ Helping evaluate effectiveness and optimization of interventions

Treatment assessments

×



### Migraine Treatment Optimization Questionnaire (MTOQ-5) Summary

MTOQ-5 is a validated tool to assess the adequacy of acute headache treatment and identify:

- Areas where improvements could be made

It is an acute treatment optimization questionnaire where patients answer Yes or No to questions on 5 topics.

**Suggested treatment optimization strategies have been proposed for “no” responses to individual questions.<sup>a</sup>**

**Consistency:** After taking your medication, are you pain free within 2 hours of most attacks?

**Functioning:** Are you able to quickly return to your normal activities (i.e. work, family, leisure, social activities) after taking your migraine medication?

**Recurrence:** Does 1 dose of medication relieve your headache and keep it away for at least 24 hours?

**Side-effects:** Is your migraine medication well tolerated?

**Global:** Are you comfortable enough with your migraine medication to be able to plan your daily activities?



M-TOQ-5 available [here](#)

Clicking this link will take you to an external site

<sup>a</sup>Treatment optimization strategies should be based on published results and treatment guidelines.

Lipton RB, et al. *Cephalalgia*. 2009;29(7):751-759.

✚ Clinically meaningful difference available.

<sup>a</sup>7 questions in total; <sup>b</sup>Not migraine-specific.

1. Dikmen PY, et al. *Heliyon*. 2023;9(5):e16187; 2. Lipton RB, et al. *Neurology*. 2003;61(3):375-382; 3. Lipton RB, et al. *Headache*. 2001;41(9):854-861; 4. Stewart WF, et al. *Pain*. 2000;88(1):41-52; 5. Lipton RB, et al. *Cephalalgia*. 2009;29(7):751-759; 6. Dowson AJ, et al. *Curr Med Res Opin*. 2004;20(7):1125-1135; 7. Cole JC, et al. *Cephalalgia*. 2009;29(11):1180-1187; 8. Reilly MC, et al. *Pharmacoeconomics*. 1993;4(5):353-365; 9. Ford JH, et al. *J Patient Rep Outcomes*. 2023;7(1):34; 10. Yang M, et al. *Cephalalgia*. 2011;31(3):357-367; 11. Tassorelli C, et al. *Cephalalgia*. 2018;38(5):815-832; 12. [Functional Impairment Scale](#). Accessed April 24, 2025.



# Migraine:

## Selected Patient Reported Outcome Measures (PROMs)

PROMs can be used to help improve migraine management by<sup>1</sup>:

- ✓ Assessing quality of life (QoL), burden of disease, disability, impact of headache on daily life, and work productivity
- ✓ Helping evaluate effectiveness and optimization of interventions

Treatment assessments



### Migraine Assessment of Current Therapy (Migraine-ACT) Summary



The 4-item Migraine-ACT questionnaire is a validated tool for use by primary care physicians to identify patients who require a change in their acute migraine treatment.<sup>1</sup>

Patients answer questions on the following topics:

- Consistency of response
- Global assessment of relief
- Emotional response
- Headache impact

**Answering “no” to over 2 questions corresponded with a need to consider changing the patient's acute medication. A higher number of “no” answers indicates a greater need to change treatments.<sup>2</sup>**

1. Does your migraine medication work consistently, in the majority of your attacks?
2. Does the headache disappear within 2 hours?
3. Are you able to function normally within 2 hours?
4. Are you comfortable enough with your medication to plan your daily activities?



Migraine-ACT available [here](#)

Clicking this link will take you to an external site

1. Dowson AJ, et al. *Curr Med Res Opin.* 2004;20(7):1125-1135; 2. Kilminster SG, et al. *Headache.* 2006;46(4):553-562.

Clinically meaningful difference available.

<sup>a</sup>7 questions in total; <sup>b</sup>Not migraine-specific.

1. Dikmen PY, et al. *Heliyon.* 2023;9(5):e16187; 2. Lipton RB, et al. *Neurology.* 2003;61(3):375-382; 3. Lipton RB, et al. *Headache.* 2001;41(9):854-861; 4. Stewart WF, et al. *Pain.* 2000;88(1):41-52; 5. Lipton RB, et al. *Cephalalgia.* 2009;29(7):751-759; 6. Dowson AJ, et al. *Curr Med Res Opin.* 2004;20(7):1125-1135; 7. Cole JC, et al. *Cephalalgia.* 2009;29(11):1180-1187; 8. Reilly MC, et al. *Pharmacoeconomics.* 1993;4(5):353-365; 9. Ford JH, et al. *J Patient Rep Outcomes.* 2023;7(1):34; 10. Yang M, et al. *Cephalalgia.* 2011;31(3):357-367; 11. Tassorelli C, et al. *Cephalalgia.* 2018;38(5):815-832; 12. [Functional Impairment Scale](#). Accessed April 24, 2025.



# Migraine:

## Selected Patient Reported Outcome Measures (PROMs)

PROMs can be used to help improve migraine management by<sup>1</sup>:

- ✓ Assessing quality of life (QoL), burden of disease, disability, impact of headache on daily life, and work productivity
- ✓ Helping evaluate effectiveness and optimization of interventions

### Treatment assessments



## Migraine-Specific Quality of Life Questionnaire 2.1 (MSQv2.1) Summary

- The MSQv2.1 measures how migraine and its treatment affect a person's health-related quality of life, including 3 main domains: role-function restrictive, role-function preventive, and emotional function.<sup>1,2</sup>

Patients respond to questions on a 6-point scale ranging from “none of the time” to “all of the time”.

Questions are asked based on the following topics<sup>4</sup>:

- **Role-function restrictive** items assess limitations imposed by migraine on the performance of an individual's daily social and work-related activities.
- **Role-function preventive** items assess how migraine attacks interrupt or prevent the performance of daily social and work-related activities.
- **Emotional function** items assess feelings of frustration and helplessness as a result of migraine.



To find out more about  
MSQv2.1 click [here](#)

Clicking this link will take you to an external site

1. Dikmen PY, et al. *Heliyon*. 2023;9(5):e16187; 2. Cole JC, et al. *Cephalalgia*. 2009;29(11):1180-1187; 3. Speck RM, et al. *Headache*. 2021;61(3):511-526; 4. Lipton RB, et al. *Cephalalgia*. 2023;43(9):1-10.

Functional Impairment  
Scale (FIS)<sup>11,12,b</sup>



4

• Functional status

Both



Clinically meaningful difference available.

<sup>a</sup>7 questions in total; <sup>b</sup>Not migraine-specific.

1. Dikmen PY, et al. *Heliyon*. 2023;9(5):e16187; 2. Lipton RB, et al. *Neurology*. 2003;61(3):375-382; 3. Lipton RB, et al. *Headache*. 2001;41(9):854-861; 4. Stewart WF, et al. *Pain*. 2000;88(1):41-52; 5. Lipton RB, et al. *Cephalalgia*. 2009;29(7):751-759; 6. Dowson AJ, et al. *Curr Med Res Opin*. 2004;20(7):1125-1135; 7. Cole JC, et al. *Cephalalgia*. 2009;29(11):1180-1187; 8. Reilly MC, et al. *Pharmacoeconomics*. 1993;4(5):353-365; 9. Ford JH, et al. *J Patient Rep Outcomes*. 2023;7(1):34; 10. Yang M, et al. *Cephalalgia*. 2011;31(3):357-367; 11. Tassorelli C, et al. *Cephalalgia*. 2018;38(5):815-832; 12. [Functional Impairment Scale](#). Accessed April 24, 2025.



# Migraine:

## Selected Patient Reported Outcome Measures (PROMs)

PROMs can be used to help improve migraine management by<sup>1</sup>:

- ✓ Assessing quality of life (QoL), burden of disease, disability, impact of headache on daily life, and work productivity
- ✓ Helping evaluate effectiveness and optimization of interventions

Treatment assessments

×

### Patient Global Impression of Change (PGIC) Summary



The PGIC evaluates a patient's impression of change in their overall status after treatment. While this scale is not directly related to migraine, it may have a wide range of use in painful conditions.<sup>1</sup>

It is a single-item measure that asks patients to rate their overall impression of their illness on a 7-point scale.

Since the start of the study, my overall status is:

1. Very much improved
2. Much improved
3. Minimally improved
4. No change
5. Minimally worse
6. Much worse
7. Very much worse



To find out more about  
PGIC click [here](#)

Clicking this link will take you to an external site

1. Dikmen PY, et al. *Heliyon*. 2023;9(5):e16187; 2. Houts CR, et al. *Headache*. 2020;60(9):2003-2013; 3. Amirfeyz R, et al. *Int Orthop*. 2009;33(1):181-185.

Functional Impairment  
Scale (FIS)<sup>11,12,b</sup>



4

• Functional status

Both

✚ Clinically meaningful difference available.

<sup>a</sup>7 questions in total; <sup>b</sup>Not migraine-specific.

1. Dikmen PY, et al. *Heliyon*. 2023;9(5):e16187; 2. Lipton RB, et al. *Neurology*. 2003;61(3):375-382; 3. Lipton RB, et al. *Headache*. 2001;41(9):854-861; 4. Stewart WF, et al. *Pain*. 2000;88(1):41-52; 5. Lipton RB, et al. *Cephalalgia*. 2009;29(7):751-759; 6. Dowson AJ, et al. *Curr Med Res Opin*. 2004;20(7):1125-1135; 7. Cole JC, et al. *Cephalalgia*. 2009;29(11):1180-1187; 8. Reilly MC, et al. *Pharmacoeconomics*. 1993;4(5):353-365; 9. Ford JH, et al. *J Patient Rep Outcomes*. 2023;7(1):34; 10. Yang M, et al. *Cephalalgia*. 2011;31(3):357-367; 11. Tassorelli C, et al. *Cephalalgia*. 2018;38(5):815-832; 12. [Functional Impairment Scale](#). Accessed April 24, 2025.



# Migraine:

## Selected Patient Reported Outcome Measures (PROMs)

PROMs can be used to help improve migraine management by<sup>1</sup>:

- ✓ Assessing quality of life (QoL), burden of disease, disability, impact of headache on daily life, and work productivity
- ✓ Helping evaluate effectiveness and optimization of interventions

### Functioning and QoL



## Work Productivity and Activity Impairment Questionnaire: Migraine v2.0 (WPAI:Migraine) Summary

WPAI:Migraine is a validated tool that measures health impairment in 4 areas: absenteeism (work time missed), presenteeism (impairment at work/reduced on-the-job effectiveness), work productivity loss (overall work impairment/absenteeism plus presenteeism), and activity impairment.<sup>1,2</sup>

**WPAI:Migraine outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity (i.e. worse outcomes).<sup>2</sup>**

Questions are asked based on the following topics:

Q1: Employment status

Q2: Hours of work missed due to problems associated with migraine

Q3: Hours of worked missed for other reasons

Q4: Hours actually worked

Q5+Q6: Degree that health problems affected work productivity and regular daily non-work activities (0–10 scale)



[WPAI available here](#)

Clicking this link will take you to an external site

1. Reilly MC, et al. *Pharmacoeconomics*. 1993;4(5):353-365; 2. Ford JH, et al. *J Patient Rep Outcomes*. 2023;7(1):34.



Clinically meaningful difference available.

<sup>a</sup>7 questions in total; <sup>b</sup>Not migraine-specific.

1. Dikmen PY, et al. *Heliyon*. 2023;9(5):e16187; 2. Lipton RB, et al. *Neurology*. 2003;61(3):375-382; 3. Lipton RB, et al. *Headache*. 2001;41(9):854-861; 4. Stewart WF, et al. *Pain*. 2000;88(1):41-52; 5. Lipton RB, et al. *Cephalalgia*. 2009;29(7):751-759; 6. Dowson AJ, et al. *Curr Med Res Opin*. 2004;20(7):1125-1135; 7. Cole JC, et al. *Cephalalgia*. 2009;29(11):1180-1187; 8. Reilly MC, et al. *Pharmacoeconomics*. 1993;4(5):353-365; 9. Ford JH, et al. *J Patient Rep Outcomes*. 2023;7(1):34; 10. Yang M, et al. *Cephalalgia*. 2011;31(3):357-367; 11. Tassorelli C, et al. *Cephalalgia*. 2018;38(5):815-832; 12. [Functional Impairment Scale](#). Accessed April 24, 2025.





# Migraine:

## Selected Patient Reported Outcome Measures (PROMs)

PROMs can be used to help improve migraine management by<sup>1</sup>:

- ✓ Assessing quality of life (QoL), burden of disease, disability, impact of headache on daily life, and work productivity
- ✓ Helping evaluate effectiveness and optimization of interventions

### Functioning and QoL



## Headache Impact Test-6 (HIT-6) Summary



HIT-6 was created to measure the impact of headache on a person's ability to function at work, at school, and in social situations.<sup>1,2</sup>

- The HIT-6 is a questionnaire consisting of 6 items that focus on daily activities.
- Patients answer questions in terms of how often they have experienced the item (e.g. never, rarely, sometimes, very often, always).

Questions are asked based on the following topics:

- Impact of headache
- Headache pain severity
- How often headaches interfere with work and usual daily activities
- Emotional distress relating to headache



To find out more about  
HIT-6 click [here](#)

Clicking this link will take you to an external site

1. Dikmen PY, et al. *Heliyon*. 2023;9(5):e16187; 2. Yang M, et al. *Cephalalgia*. 2011;31(3):357-367.

Functional Impairment  
Scale (FIS)<sup>11,12,b</sup>



4

• Functional status

Both

Clinically meaningful difference available.

<sup>a</sup>7 questions in total; <sup>b</sup>Not migraine-specific.

1. Dikmen PY, et al. *Heliyon*. 2023;9(5):e16187; 2. Lipton RB, et al. *Neurology*. 2003;61(3):375-382; 3. Lipton RB, et al. *Headache*. 2001;41(9):854-861; 4. Stewart WF, et al. *Pain*. 2000;88(1):41-52; 5. Lipton RB, et al. *Cephalalgia*. 2009;29(7):751-759; 6. Dowson AJ, et al. *Curr Med Res Opin*. 2004;20(7):1125-1135; 7. Cole JC, et al. *Cephalalgia*. 2009;29(11):1180-1187; 8. Reilly MC, et al. *Pharmacoeconomics*. 1993;4(5):353-365; 9. Ford JH, et al. *J Patient Rep Outcomes*. 2023;7(1):34; 10. Yang M, et al. *Cephalalgia*. 2011;31(3):357-367; 11. Tassorelli C, et al. *Cephalalgia*. 2018;38(5):815-832; 12. [Functional Impairment Scale](#). Accessed April 24, 2025.



# Migraine:

## Selected Patient Reported Outcome Measures (PROMs)

PROMs can be used to help improve migraine management by<sup>1</sup>:

- ✓ Assessing quality of life (QoL), burden of disease, disability, impact of headache on daily life, and work productivity
- ✓ Helping evaluate effectiveness and optimization of interventions

### Functioning and QoL



## Functional Impairment Scale (FIS) Summary



The FIS is a 4-point single global item scale that addresses functional status and intensity of impairment during daily activities.<sup>1,2</sup>

**While completing the FIS, patients rate their impairment on a scale of 0 (no disability) to 3 (severe impairment during performance of daily activities).**

3 = Severe impairment during performance of daily activity

2 = Moderate impairment during performance of daily activity

1 = Mild impairment during performance of daily activity

0 = Normal level of functioning: no disability



**FIS available [here](#)**

Clicking this link will take you to an external site

1. Tassorelli C, et al. *Cephalalgia*. 2018;38(5):815-832; 2. Silberstein SD, et al. *Headache*. 2007;47(5):673-682;

### Functioning and QoL

**Headache Impact Test-6 (HIT-6)<sup>10</sup>**



6

- Activity Impairment
- Impact of headache (pain, impairment, emotional distress)

Preventive

**Functional Impairment Scale (FIS)<sup>11,12,b</sup>**



4

- Functional status

Both

Clinically meaningful difference available.

<sup>a</sup>7 questions in total; <sup>b</sup>Not migraine-specific.

1. Dikmen PY, et al. *Heliyon*. 2023;9(5):e16187; 2. Lipton RB, et al. *Neurology*. 2003;61(3):375-382; 3. Lipton RB, et al. *Headache*. 2001;41(9):854-861; 4. Stewart WF, et al. *Pain*. 2000;88(1):41-52; 5. Lipton RB, et al. *Cephalalgia*. 2009;29(7):751-759; 6. Dowson AJ, et al. *Curr Med Res Opin*. 2004;20(7):1125-1135; 7. Cole JC, et al. *Cephalalgia*. 2009;29(11):1180-1187; 8. Reilly MC, et al. *Pharmacoeconomics*. 1993;4(5):353-365; 9. Ford JH, et al. *J Patient Rep Outcomes*. 2023;7(1):34; 10. Yang M, et al. *Cephalalgia*. 2011;31(3):357-367; 11. Tassorelli C, et al. *Cephalalgia*. 2018;38(5):815-832; 12. [Functional Impairment Scale](#). Accessed April 24, 2025.